Financial Snapshot
Revenues
Revenues
Revenue YoY Change
Revenues
Expenses
Cost Of Revenues
Gross Profit
Gross Profit Margin
Gross Profit
Selling, General & Admin Expense
Research & Development
Depreciation, Depletion & Amortization
SGA Expense to Gross Profit Ratio
R&D To Gross Profit Ratio
DDA To Gross Profit Ratio
Operating Expenses Total
Operating Profits/Loss
Operational Expenses
Interest Expenses
Interest Expenses To Operating Income %
Other Expense/Income
Interest & Other Expense/Income
Income/Loss
Pretax Income
Income Tax
Net Profits/Loss
Pretax Income YoY Change
Income Tax Rate
Net Profits/Loss YoY Change
Basic EPS
Net Income To Revenue Ratio
Pretax & Net Income
Assets & Liabilities
Cash & Short-Term Investments
Cash & Equivalents
Cash To Operating Expenses Ratio
Inventory
Receivables
Total Short-Term Assets
Property, Plant And Equipment
Long-Term Investments
Total Long-Term Assets
Total Assets
Net Income To Total Assets Percentage
Accounts Payable
Short-Term Debt
Long Term Debt Due
Total Short-Term Liabilities
Long-Term Debt
Other Long-Term Liabilities
Total Long-Term Liabilities
Total Liabilities
Short-Term To Long-Term Debt Ratio
Short-Term Assets To Debt Ratio
Long-Term Debt To Net Income Ratio
Assets & Liabilities
Ownership
Basic Shares Outstanding
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares
Stock Issuance & Repurchase
Ownership Data
Return On Shareholders' Equity
Book Value
Free Cash Flow
Free Cash Flow YoY
Free Cash Flow Margin
Dividends
Dividends
Stock Price
About Skye Bioscience, Inc.
Skye Bioscience, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of cannabinoid-based therapeutics. The company is headquartered in San Diego, California and currently employs 11 full-time employees. The company went IPO on 2014-02-24. The firm's clinical assets focus on the modulation of cannabinoid receptor 1 (CB1) to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. Its Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion (SBI-100 OE), a CB1 agonist (activator), being developed for the treatment of glaucoma and ocular hypertension. The firm's Phase 2 study in obesity is designed to evaluate nimacimab's weight loss potential either as a single agent or in combination with a glucagon-like peptide-1 (GLP-1) agonist like semaglutide.
Industry: Pharmaceutical Preparations Peers: Bone Biologics Corp American CryoStem Corp Protagenic Therapeutics, Inc.\new NeuBase Therapeutics, Inc. Eterna Therapeutics Inc. MetaVia Inc. Transcode Therapeutics, Inc.
